Enanta Pharmaceuticals, Inc. (ENTA)
13.60
-0.20
(-1.45%)
USD |
NASDAQ |
Aug 28, 16:00
13.58
-0.02
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals EPS Diluted (Quarterly) : -0.6704 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6704 |
| March 31, 2026 | -0.4508 |
| December 31, 2025 | -0.4153 |
| September 30, 2025 | -0.8746 |
| June 30, 2025 | -0.854 |
| March 31, 2025 | -1.060 |
| December 31, 2024 | -1.050 |
| September 30, 2024 | -1.360 |
| June 30, 2024 | -1.070 |
| March 31, 2024 | -1.472 |
| December 31, 2023 | -1.584 |
| September 30, 2023 | -1.335 |
| June 30, 2023 | -1.856 |
| March 31, 2023 | -1.790 |
| December 31, 2022 | -1.392 |
| September 30, 2022 | -1.270 |
| June 30, 2022 | -1.531 |
| March 31, 2022 | -1.635 |
| December 31, 2021 | -1.477 |
| September 30, 2021 | -1.216 |
| June 30, 2021 | -1.189 |
| March 31, 2021 | -1.093 |
| December 31, 2020 | -0.4145 |
| September 30, 2020 | -1.462 |
| June 30, 2020 | -0.7125 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.3014 |
| December 31, 2019 | 0.6471 |
| September 30, 2019 | 0.4403 |
| June 30, 2019 | 0.3334 |
| March 31, 2019 | 0.1966 |
| December 31, 2018 | 1.250 |
| September 30, 2018 | 1.302 |
| June 30, 2018 | 0.97 |
| March 31, 2018 | 0.61 |
| December 31, 2017 | 0.59 |
| September 30, 2017 | 1.86 |
| June 30, 2017 | -0.44 |
| March 31, 2017 | -0.28 |
| December 31, 2016 | -0.26 |
| September 30, 2016 | -0.0947 |
| June 30, 2016 | -0.06 |
| March 31, 2016 | -0.09 |
| December 31, 2015 | 1.36 |
| September 30, 2015 | 0.29 |
| June 30, 2015 | 0.13 |
| March 31, 2015 | 1.49 |
| December 31, 2014 | 2.18 |
| September 30, 2014 | -0.27 |
| June 30, 2014 | 2.61 |
| March 31, 2014 | -0.28 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -0.222 |
| AbbVie, Inc. | 2.033 |
| Coherus Oncology, Inc. | -0.1312 |
| BridgeBio Pharma, Inc. | -0.7775 |
| RenovoRx, Inc. | -0.0616 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.50M |
| Revenue (Quarterly) | 14.36M |
| Total Expenses (Quarterly) | 33.86M |
| Enterprise Value | 388.57M |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -17.73% |
| Normalized Earnings Yield | -17.73 |